[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631962":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":39,"centralContacts":44,"locations":53,"responsibleParty":126,"collaborators":128,"id":131,"slug":132,"hasResults":133,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":133,"sex":139,"minAge":140,"maxAge":34,"enrollmentInfo":141,"targetDuration":34,"studyType":144,"phases":145,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":159,"whyStopped":34,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},{"fullName":5,"class":6},"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","OTHER",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Prasugrel 12 months DAPT","ACTIVE_COMPARATOR","Prasugrel-based 12 months DAPT",[13],"Drug: Prasugrel",{"label":15,"type":16,"description":17,"interventionNames":18},"Prasugrel abbreviated DAPT","EXPERIMENTAL","Prasugrel-Based DAPT for 1 to 3 Months, Followed by Prasugrel Monotherapy Through 12 Months After MI",[13],{"label":20,"type":16,"description":21,"interventionNames":22},"Ticagrelor 12 months DAPT","Ticagrelor-based 12 months DAPT",[23],"Drug: Ticagrelor",{"label":25,"type":16,"description":26,"interventionNames":27},"Ticagrelor abbreviated DAPT","Ticagrelor-Based DAPT for 1 to 3 Months, Followed by Prasugrel Monotherapy Through 12 Months After MI",[23],[29,35],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","Prasugrel","Prasugrel during 12 months",[9,15],null,{"type":30,"name":36,"description":37,"armGroupLabels":38,"otherNames":34},"Ticagrelor","Ticagrelor plus aspirin",[20,25],[40],{"name":41,"affiliation":42,"role":43},"Borja Ibanez, MD PhD","Centro Nacional de Investigaciones Cardiovasculares (CNIC) & Fundacion Jimenez Díaz University Hospital (IIS-FJD)","PRINCIPAL_INVESTIGATOR",[45,50],{"name":46,"role":47,"phone":48,"phoneExt":34,"email":49},"Noemi Escalera, PT","CONTACT","+34 91 4531200 (ext 5401)","noemi.escalera@cnic.es",{"name":51,"role":47,"phone":34,"phoneExt":34,"email":52},"Lucia Llanos, MD PhD","lucia.llanos@quironsalud.es",[54,70,84,98,112],{"facility":55,"status":34,"city":56,"state":34,"zip":34,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Mater Private Network Dublin","Dublin","Ireland","IE",{"type":60,"coordinates":61},"Point",[62,63],-6.24889,53.33306,{"lat":63,"lon":62},[66],{"name":67,"role":47,"phone":68,"phoneExt":34,"email":69},"Robert Byrne, MD PhD","+34 914531200","Robert.Byrne@materprivate.ie",{"facility":71,"status":34,"city":72,"state":34,"zip":34,"country":73,"countryCode":74,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Paula Stradiņa klīniskā universitates slimnīca","Riga","Latvia","LV",{"type":60,"coordinates":76},[77,78],24.10589,56.946,{"lat":78,"lon":77},[81],{"name":82,"role":47,"phone":68,"phoneExt":34,"email":83},"Andrejs Erglis, MD PhD","a.a.erglis@stradini.lv",{"facility":85,"status":34,"city":86,"state":34,"zip":34,"country":87,"countryCode":88,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"Oslo University Hospital, Ullevål.","Oslo","Norway","NO",{"type":60,"coordinates":90},[91,92],10.74609,59.91273,{"lat":92,"lon":91},[95],{"name":96,"role":47,"phone":68,"phoneExt":34,"email":97},"Sigrun Halvorsen, MD PhD","sigrun.halvorsen@medisin.uio.no",{"facility":99,"status":34,"city":100,"state":34,"zip":34,"country":101,"countryCode":102,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Saint John Paul II Hospital in Cracow","Krakow","Poland","PL",{"type":60,"coordinates":104},[105,106],19.93658,50.06143,{"lat":106,"lon":105},[109],{"name":110,"role":47,"phone":34,"phoneExt":34,"email":111},"Jacek Legutko, MD PhD","jacek.legutko@outlook.com",{"facility":113,"status":34,"city":114,"state":34,"zip":34,"country":115,"countryCode":116,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"Fundación Jiménez Díaz University Hospital","Madrid","Spain","ES",{"type":60,"coordinates":118},[119,120],-3.70256,40.4165,{"lat":120,"lon":119},[123],{"name":124,"role":47,"phone":68,"phoneExt":34,"email":125},"Sandra Gómez-Talavera, MD","sandra.gomezt@quironsalud.es",{"type":127,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR",[129],{"name":130,"class":6},"Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III","100631962","phase-4-dual-antiplatelet-therapy-strategies-after-acute-myocardial-infarction-undergoing-pci-prasugrel-vs-ticagrelor--12-months-vs-1-3-months-100631962",false,"NCT07507500","Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months","Strategies for Antiplatelet Management Following Acute Coronary Syndrome","STREAMLINE","Inclusion Criteria:\n\n* ≥18 years old\n* Admitted because of an acute MI (either STEMI or NSTEMI).\n* Invasive management during index admission with successful PCI.\n* Able to consent.\n\nExclusion Criteria:\n\n* Indication for oral anticoagulation therapy.\n* Intolerance, contraindication or known allergy to either aspirin, prasugrel or ticagrelor.\n* Prior history of ischaemic or haemorrhagic stroke or transient ischaemic attack.\n* Patients with active bleeding or known bleeding disorders.\n* Patients with known moderate or severe hepatic dysfunction (Child-Pugh Class B or Class C).\n* Known intracranial aneurism, arteriovenous malformation or neoplasm.\n* Patients with chronic kidney disease requiring dialysis.\n* Any disorder that may interfere with drug absorption.\n* Pregnancy or current lactation.\n* Concomitant use of potent CYP3A inhibitors or inducers.\n* Planned elective surgery that cannot be deferred 12 months before randomization, requiring interruption of antiplatelet therapy.\n* Any medical condition that, in the investigator´s judgment, would seriously limit life expectancy (less than one year)\n* Active participation in other clinical trials.","ALL","18 Years",{"count":142,"type":143},8100,"ESTIMATED","INTERVENTIONAL",[146],"PHASE4","This study is testing different blood-thinning treatment strategies for people who have had a heart attack and were successfully treated with a coronary stent procedure (PCI). All strategies tested are already approved for this condition and used inversally. This study will define which of the approved strategies is the best one.\n\nAfter PCI, patients usually receive two antiplatelet medicines for up to 12 months to help prevent another heart attack or stroke, but this treatment can also increase bleeding risk. This study will compare a shorter course of dual antiplatelet therapy followed by one antiplatelet medicine alone versus the standard 12-month course. In addition, the study will compare two commonly used antiplatelet drugs, prasugrel and ticagrelor. The goal is to find out which strategy best prevents death, heart attack, or stroke while minimizing serious bleeding.\n\nThis study is not testing any new intervention, rather comparing approved drugs and approved durations of use.",[149],"Myocardial Infarction (MI)",[151,152,153,154,155,156,157,158],"acute coronary syndrome","infarction","DAPT","dual antiplatelet therapy","prasugrel","ticagrelor","ischemic event","bleeding","NOT_YET_RECRUITING","2026-03-27",{"date":162,"type":163},"2026-04-02","ACTUAL",{"date":165,"type":143},"2026-07",{"date":167,"type":143},"2030-01",{"name":5,"class":6},5]